pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TEVATEVA PHARMACEUTICAL INDUSTRIES LTD

$TEVA42.57-4.34%
Tel Aviv, ILupdated 14h ago

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
10
approvals ytd
4
recalls ytd
3

Pipeline(6)

pipeline depth6 products
Phase 2: 3Phase 3: 1Marketed: 1pre_registration: 1
3Phase 21Phase 31Marketed1pre_registration
Marketed
omacetaxine mepesuccinate
Myelodysplastic Syndrome (Preleukemia)
Phase 3
duvakitug
Crohn's Disease (Regional Enteritis)
Phase 2
CEP-11981
Pancreatic Cancer
Vascular endothelial growth factor receptorAngiopoietin-1 receptor
Phase 2
TEV-408
Celiac Disease
Phase 2
emrusolmin
Multiple System Atrophy (Multi-System Degeneration)
pre_registration
olanzapine ER
Schizophrenia
D2-like dopamine receptor5-hydroxytryptamine receptor 2C

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$TEVA42.57-4.34%
13d ago
TEVA PHARMACEUTICAL INDUSTRIES LTD earnings
TEVA PHARMACEUTICAL INDUSTRIES LTD
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view TEVA PHARMACEUTICAL INDUSTRIES LTD jobs →

News

  • AstraZeneca, Calidi, Tempest make significant workforce cuts
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 18h ago
  • Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
    Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.
    fiercebiotech · 4d ago
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 4d ago
  • Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
    Windward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.
    fiercebiotech · 8d ago
  • Novartis ends BioArctic pact; Two VC firms raise inaugural funds
    Plus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug…
    endpoints · 13d ago
  • UniQure gets an FDA decision date; Teva scraps brain drug study
    The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
    biopharma_dive · 13d ago
  • Teva ends trial of one of its original line-up of innovative meds over futility
    Teva has given up on a key trial of one of its original line-up of innovative medicines.
    fiercebiotech · 15d ago
  • UK lands £500M in biopharma pledges; Teva to shutter New Jersey site
    Plus, news about Esteve and Regeneron. UK pulls in £500M investment: As part of the UK’s Autumn budget, Vertex Pharmaceuticals said it will invest over £300 million in a new R&D site in Oxford, UK ...
    endpoints · 18d ago
  • Webinar: The China question: Can US biotechs lead as investment heads east?
    In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.
    biospace · 1mo ago
  • First Tracks climbs on ‘impressive’ celiac study data
    Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.
    biopharma_dive · 1mo ago
view all news mentions →
identifiers
ticker
$TEVA
SEC CIK
0000818686
country
IL
source
sec_tickers
top tags
Oncology2IBD (Crohn's + UC)1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 50m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?